The following data were collected from a consecutive series of 111 patients in the 4-week observation stage: (i) demographic data, including sex, age, severity of hospitalization, and histories of chronic disorder (chronic cardiovascular disease, chronic respiratory disease, chronic cerebrovascular illness, and diabetes); and (ii) serum biochemical data, including antibodies against SARS-CoV-2 (IgM and IgG), hs-CRP, IL-6 and lymphocyte subsets [including the percentage of CD3 + /CD8 + /CD4 + /natural killer (NK) cells/B lymphocytes].

Peripheral venous blood samples were obtained using strict aseptic techniques from patients at weeks 0, 2 and 4. IgM and IgG were detected by the colloidal gold method using a novel coronavirus (2019-nCoV) IgM/IgG antibody detection kit (Livzon Reagent Co., Ltd., Zhuhai, China). Hs-CRP was determined by a Modular PPI automatic biochemical analyser (Roche Diagnostics (Shanghai) Co., Ltd., Shanghai, China). IL-6 was determined by a fully automatic electrochemiluminescence immunoassay system (Cobas e411 analyser series, Roche Diagnostics (Shanghai) Co., Ltd., Shanghai, China). Lymphocyte subsets were detected and counted by a BD FACSCalibur flow cytometer (BD, Bioscience, CA, USA). The following antibodies (BD, Bioscience, CA, USA) were used: FITC anti-human CD14, FITC-conjugated anti-CD4, ECD-conjugated anti-CD3, PC5-conjugated anti-CD8, PE-conjugated anti-CD19, and PC7-conjugated anti-CD16CD45.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.